Back to results
US 8,980,898 B2Granted
Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
AssigneeParion Sciences, Inc.
InventorsMichael Ross Johnson, William Robert Thelin, Richard C. Boucher
Life of this patent
Estimating the term…
Abstract
Sodium channel blockers represented by the formula: are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.
Claims19
A compound represented by formula (I):
- and racemates, enantiomers, diastereomers, tautomers, polymorphs, pseudopolymorphs and pharmaceutically acceptable salts, thereof,
- wherein:
- X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;
- Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or —N(R2)2;
- R1 is hydrogen or lower alkyl;
- each R2 is, independently, —R7, —(CH2)m—OR8, —(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(═O)NR7R10, —(CH2)n—(Z)g—R7, —(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, or
- R3 and R4 are each, independently, hydrogen, lower alkyl, hydroxyl-lower alkyl, phenyl, (phenyl)-lower alkyl, (halophenyl)-lower alkyl, ((lower-alkyl)phenyl)-lower-alkyl, ((lower-alkoxy)phenyl)-lower-alkyl, (naphthyl)-lower-alkyl, or (pyridyl)-lower-alkyl, or a group represented by formula A or formula B, with the proviso that at least one of R3 and R4 is a group represented by the formula A or formula B;
- —(C(RL)2)o-x-(C(RL)2)pA1 formula A:
- —(C(RL)2)o-x-(C(RL)2)pA2 formula B:
- A1 is a C6-C15-membered aromatic carbocycle substituted with at least one R5 and the remaining substituents are R6;
- A2 is a six to fifteen-membered aromatic heterocycle substituted with at least one R5 and the remaining substituents are R6 wherein said aromatic heterocycle comprises 1-4 heteroatoms selected from the group consisting of O, N, and S;
- each RL is, independently, —R7, —(CH2)n—OR8, —O—(CH2)m—OR8, —(CH2)n—NR7R10, —O—(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —O—(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —O—(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(═O)NR7R10, —O—(CH2)m—C(═O)NR7R10, —(CH2)n—(Z)g—R7, —O—(CH2)m—(Z)g—R7, —(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, —O—(CH2)m—CO2R7, —OSO3H, —O-glucuronide, —O-glucose,
- each o is, independently, an integer from 0 to 10;
- each p is, independently, an integer from 0 to 10;
- with the proviso that the sum of o and p in each contiguous chain is from 1 to 10;
- each x is, independently, O, NR10, C(═O), CHOH, C(═N—R10), CHNR7R10, or a single bond;
- each R5 is, independently, -Link-(CH2)m-CAP, -Link-(CH2)n(CHOR8)(CHOR8)n-CAP, -Link-(CH2CH2O)m—CH2-CAP, -Link-(CH2CH2O)m—CH2CH2-CAP, -Link-(CH2)m—(Z)g-CAP, -Link-(CH2)n(Z)g—(CH2)m-CAP, -Link-(CH2)n—NR13—CH2(CHOR8)(CHOR8)n-CAP, -Link-(CH2)n—(CHOR8)mCH2—NR13—(Z)g-CAP, -Link-(CH2)nNR13—(CH2)m(CHOR8)mCH2NR13—(Z)g-CAP, -Link-(CH2)m—(Z)g—(CH2)m-CAP, -Link-NH—C(═O)—NH—(CH2)m-CAP, -Link-(CH2)m—C(═O)NR13—(CH2)m-CAP, -Link-(CH2)n—(Z)g—(CH2)m—(Z)g-CAP, or -Link-Zg—(CH2)m-Het-(CH2)m-CAP;
- each R6 is, independently, R5, —R7, —OR11, —N(R7)2, —(CH2)m—OR8, —O—(CH2)m—OR8, —(CH2)n—NR7R10, —O—(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —O—(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —O—(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(═O)NR7R10, —O—(CH2)m—C(═O)NR7R10, —(CH2)n—(Z)g—R7, —O—(CH2)m—(Z)g—R7, —(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, —O—(CH2)m—CO2R7, —OSO3H, —O-glucuronide, —O-glucose,
- wherein when two R6 are —OR11 and are located adjacent to each other on the aromatic carbocycle or aromatic heterocycle, the two OR11 may form a methylenedioxy group;
- each R7 is, independently, hydrogen, lower alkyl, phenyl, substituted phenyl or —CH2(CHOR8)m—CH2OR8;
- each R8 is, independently, hydrogen, lower alkyl, —C(═O)—R11, glucuronide, 2-tetrahydropyranyl, or
- each R9 is, independently, —CO2R7, —CON(R7)2, —SO2CH3, —C(═O)R7, —CO2R13, —CON(R13)2, —SO2CH2R13, or —C(═O)R13;
- each R10 is, independently, —H, —SO2CH3, —CO2R7, —C(═O)NR7R9, —C(═O)R7, or —CH2—(CHOH)n—CH2OH;
- each Z is, independently, —(CHOH)—, —C(═O)—, —(CHNR7R10)—, —(C═NR10)—, —NR10—, —(CH2)n—, —(CHNR13R13)—, —(C═NR13)—, or —NR13—;
- each R11 is, independently, hydrogen, lower alkyl, phenyl lower alkyl or substituted phenyl lower alkyl;
- each R12 is, independently, —SO2CH3, —CO2R7, —C(═O)NR7R9, —C(═O)R7, —CH2(CHOH)n—CH2OH, —CO2R7, —C(═O)NR7R7, or —C(═O)R7;
- each R13 is, independently, hydrogen, —OR7, R10, R11 or R12;
- each g is, independently, an integer from 1 to 6;
- each m is, independently, an integer from 1 to 7;
- each n is, independently, an integer from 0 to 7;
- each -Het- is, independently, —N(R7)—, —N(R10)—, —S—, —SO—, —SO2—;
- —O—, —SO2NH—, —NHSO2—, —NR7CO—, —CONR7—, —N(R13)—, —SO2NR13—, —NR13CO—, or —CONR13—;
- each Link is, independently, —O—, —(CH2)n—, —O(CH2)m—, —NR13—C(═O)—NR13—, —NR13—C(═O)—(CH2)m—, —C(═O)NR13—(CH2)m−, —(CH2)n—(Z)g—(CH2)n—, —S—, —SO—, —SO2—, —SO2NR7—, —SO2NR10—, or -Het-;
- each CAP is
31 more elements
A compound represented by one of the following formulas:
- or a pharmaceutically active salt thereof.
The hydrochloride salt of:
Dependencies are inferred from the claim text.